Want to see AU:EMD full AI Analyst Report?
EMD Stock Chart & Stats
AU$0.04
<AU$0.01(9.09%)
At close: 4:00 PM EDT
AU$0.04
<AU$0.01(9.09%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.08
Previous CloseN/A
Volume920.05K
Average Volume (3M)1.07M
Market Cap
AU$35.49M
Enterprise ValueAU$25.76
Total Cash (Recent Filing)AU$7.29M
Total Debt (Recent Filing)AU$787.38K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,561,040
10 Day Avg. Volume1,164,523
30 Day Avg. Volume1,067,099
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.35
Price to Sales (P/S)7.63
P/FCF Ratio-6.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$9.70M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe strong 2026 revenue rebound indicates renewed commercial activity and improving demand for the company’s offerings. If maintained, a larger revenue base could improve operating leverage, support continued clinical development, and strengthen the company’s ability to build a sustainable healthcare platform.
Low LeverageVery low debt relative to equity gives Emyria greater financial flexibility than its earlier capital structure provided. Lower leverage reduces fixed financing pressure and may leave more capacity to fund research, services, and strategic initiatives while the company works toward profitability.
Mental Health PlatformEmyria combines direct mental health services with clinical research and therapeutic development, creating a business model linked to a structurally important healthcare need. This combination may support knowledge accumulation across activities and provide multiple avenues for longer-term growth.
Bears Say
Persistent Net LossesOngoing sizable net losses show that the current revenue base is not yet supporting the company’s cost structure. Deeply negative margins reduce the likelihood of near-term self-funded expansion and make successful execution of the growth strategy increasingly important for long-term financial sustainability.
Negative Cash GenerationPersistent operating and free cash outflows indicate that Emyria continues to consume cash despite the recent revenue rebound. Continued burn can require reliance on external funding or existing reserves, potentially limiting investment choices and increasing pressure to demonstrate durable commercial progress.
Negative Shareholder ReturnsNegative return on equity indicates that the company is not currently converting its equity base into profitable returns for shareholders. If losses continue, accumulated value can be eroded even with low leverage, weakening the balance sheet’s ability to support future growth.
Emyria Ltd News
EMD FAQ
What was Emyria Ltd’s price range in the past 12 months?
Emyria Ltd lowest share price was AU$0.04 and its highest was AU$0.08 in the past 12 months.
What is Emyria Ltd’s market cap?
Emyria Ltd’s market cap is AU$35.49M.
When is Emyria Ltd’s upcoming earnings report date?
Emyria Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 178 days.
How were Emyria Ltd’s earnings last quarter?
Emyria Ltd released its earnings results on Sep 01, 2026. The company reported -AU$0.005 earnings per share for the quarter.
Is Emyria Ltd overvalued?
According to Wall Street analysts Emyria Ltd’s price is currently Overvalued.
Does Emyria Ltd pay dividends?
Emyria Ltd does not currently pay dividends.
What is Emyria Ltd’s EPS estimate?
Emyria Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emyria Ltd have?
Emyria Ltd has 806,561,040 shares outstanding.
What happened to Emyria Ltd’s price movement after its last earnings report?
Emyria Ltd reported an EPS of -AU$0.005 in its last earnings report. Following the earnings report the stock price went up 2.222%.
Which hedge fund is a major shareholder of Emyria Ltd?
Currently, no hedge funds are holding shares in AU:EMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emyria Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
73.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Emyria Ltd
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Technical Analysis
Cogstate Ltd
―
Oneview Healthcare Chess Depository Interests repr 1
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh
―